View Post

Phase 3 OlympiA Trial for HER2-Negative Breast Cancer Moves to Early Primary Analysis Per IDMC Recommendation

In Clinical Studies News by Barbara Jacoby

By: Hannah Slater From: In the OlympiA trial, patients with high-risk HER2-negative breast cancer were randomized 1:1 to receive either olaparib or placebo for 12 months. A planned interim analysis found that the phase 3 OlympiA trial (NCT02032823) crossed the superiority boundary for its primary end point of invasive disease-free survival (iDFS) and demonstrated a sustainable, clinically relevant treatment …

View Post

Germline BRCA-Mutated Breast Cancer Does Not Increase Risk of Adverse Pregnancy Outcomes

In In The News by Barbara Jacoby

By: Maggie L. Shaw From: Women with early-onset germline BRCA-mutated breast cancer can have subsequent pregnancies without increasing their risk for disease recurrence, according to the authors of a recent study in Journal of Clinical Oncology. Women who have had germline BRCA-mutated breast cancer before the age of 40 were shown in a recent study to be able to …